Insider Selling: Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Sells 2,324 Shares of Stock

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard sold 2,324 shares of Cumberland Pharmaceuticals stock in a transaction on Friday, June 28th. The stock was sold at an average price of $6.37, for a total value of $14,803.88. Following the completion of the transaction, the director now owns 73,084 shares in the company, valued at $465,545.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ CPIX traded down $0.19 during mid-day trading on Friday, reaching $5.67. The company had a trading volume of 16,672 shares, compared to its average volume of 13,789. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.67 and a current ratio of 2.07. The stock has a market capitalization of $89.34 million, a PE ratio of -47.25 and a beta of 0.14. The business has a 50-day moving average price of $6.27. Cumberland Pharmaceuticals, Inc. has a 1-year low of $4.83 and a 1-year high of $7.00.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.22. The business had revenue of $11.90 million for the quarter, compared to analysts’ expectations of $10.70 million. Cumberland Pharmaceuticals had a positive return on equity of 2.54% and a negative net margin of 10.57%. Sell-side analysts predict that Cumberland Pharmaceuticals, Inc. will post 0.28 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on CPIX shares. Zacks Investment Research upgraded Investors Real Estate Trust Reit from a “sell” rating to a “hold” rating in a report on Thursday, May 23rd. TheStreet upgraded Medpace from a “c” rating to a “b-” rating in a report on Wednesday, April 10th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Featured Article: How are the companies in the S&P 500 selected?

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.